WindMIL Therapeutics

About WindMIL Therapeutics

When it comes to cell therapy – cell source matters. At WindMIL, we are harnessing the power of bone marrow derived lymphocytes (MILs) to develop ground-breaking immunotherapies to treat cancer patients. The bone marrow is a natural reservoir of T cells with unique advantages including inherent tumor-specificity. We have perfected an efficient and rapid process to extract, activate and expand MILs for future commercial applications. Our lead program is in a large Phase 2b study in high-risk multiple myeloma with additional programs in solid tumors using MILs advancing to the clinic. We are also advancing programs to supercharge MILs through genetic-modification.

YEAR FOUNDED:
2015

LEADERSHIP:
Founders: Ivan Borrello, MD and Kimberly Noonan, PhD
CEO: Brian Halak, PhD
CMO: Dr. Steven Fischkoff
CSO: Kimberly Noonan, PhD

TECHNOLOGY
Please click here for WindMIL's technology.